{"id":678969,"date":"2023-11-30T09:24:02","date_gmt":"2023-11-30T09:24:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=678969"},"modified":"2023-11-30T09:24:02","modified_gmt":"2023-11-30T09:24:02","slug":"pancreatic-cancer-pipeline-insights-report-2023-updated-erytech-pharma-jiangsu-hengrui-medicine-co-ltd-fibrogen-novartis-ag-ab-science-eleison-pharmaceuticals-cornerstone-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/pancreatic-cancer-pipeline-insights-report-2023-updated-erytech-pharma-jiangsu-hengrui-medicine-co-ltd-fibrogen-novartis-ag-ab-science-eleison-pharmaceuticals-cornerstone-pharmaceuticals_678969.html","title":{"rendered":"Pancreatic Cancer Pipeline Insights Report 2023 (Updated) | ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1701351203.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Pancreatic Cancer Pipeline Insights Report 2023 (Updated) | ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals\" src=\"https:\/\/www.abnewswire.com\/uploads\/1701351203.jpeg\" alt=\"Pancreatic Cancer Pipeline Insights Report 2023 (Updated) | ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;Pancreatic Cancer Pipeline Insight 2023&rdquo; report provides comprehensive insights about 290+ companies and 300+ pipeline drugs in the Pancreatic Cancer pipeline landscape. It covers the Pancreatic Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pancreatic Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Pancreatic Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s Pancreatic Cancer pipeline report depicts a robust space with 290+ active players working to develop 300+ pipeline therapies for Pancreatic Cancer treatment.<\/li>\n<li>The leading companies working in the Pancreatic Cancer Market include ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp &amp; Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others.<\/li>\n<li>Promising Pancreatic Cancer Pipeline Therapies in the various stages of development include Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, and others.<\/li>\n<li>September 2023: Golden Biotechnology Corporation announced a study of Phase 1 &amp; 2 Clinical trials for Antroquinonol. The proposed clinical trial is a Phase I\/II study designed to evaluate antroquinonol in combination with nab-paclitaxel and gemcitabine in first line treatment na&iuml;ve subjects with Stage IV metastatic pancreatic carcinoma. The first part of study will focus on the treatment of pancreatic cancer with 200 mg TID and 300 mg TID, clinical treatment duration of 4 weeks, to determine the MTD or MFD (based on PK and capsules strength) of antroquinonol in combination with a standard dose regimen of nab-paclitaxel and gemcitabine.<\/li>\n<li>October 2023: Helix BioPharma Corporation announced a study of Phase 1 &amp; 2 clinical trials for L-DOS47 and Doxorubicin. This study will evaluate the safety and tolerability of escalating doses of L-DOS47 in combination with doxorubicin, as well as preliminary anti-tumor activity in patients with previously treated advanced pancreatic cancer.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample and discover the recent advances in Pancreatic Cancer Treatment Drugs @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Pancreatic Cancer Pipeline Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">In the Pancreatic Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Pancreatic Cancer Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Pancreatic cancer is a disease in which malignant or cancer cells form in the tissues of the pancreas. Pancreatic cancer begins in the tissues of the pancreas &ndash; an organ in the abdomen that lies behind the lower part of the stomach. Pancreatic cancer most frequently arises from pancreatic intraepithelial neoplasia (PanIN), the classic pre-neoplastic lesions, but can also arise from larger precursor lesions, namely, intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Find out more about Pancreatic Cancer Therapeutics Assessment @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Pancreatic Cancer Preclinical and Discovery Stage Products<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Pancreatic Cancer Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>NIS793: Novartis AG<\/li>\n<li>Devimistat: Cornerstone Pharmaceuticals<\/li>\n<li>Masitinib: AB Science<\/li>\n<li>SBP-101: Panbela Therapeutics<\/li>\n<li>TAS-102: Taiho Pharmaceutical Co., Ltd.<\/li>\n<li>RAIN-32: Rain Oncology<\/li>\n<li>IMX-110: Immix Biopharma<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Pancreatic Cancer Pipeline Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">There are approx. 290+ key companies which are developing the Pancreatic Cancer therapies. The Pancreatic Cancer companies which have their Pancreatic Cancer drug candidates in the most advanced stage, i.e. phase III include, Novartis.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Pancreatic Cancer Pipeline Report covers around&nbsp;300+ products&nbsp;under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Parenteral<\/li>\n<li>Topical<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Pancreatic Cancer Pipeline Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Recombinant fusion proteins<\/li>\n<li>Small molecule<\/li>\n<li>Monoclonal antibody<\/li>\n<li>Peptide<\/li>\n<li>Polymer<\/li>\n<li>Gene therapy<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the emerging Pancreatic Cancer Pipeline Therapies @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Pancreatic Cancer Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Pancreatic Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Pancreatic Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Pancreatic Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<li>Pancreatic Cancer Companies- ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp &amp; Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others.<\/li>\n<li>Pancreatic Cancer Pipeline Therapies- Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dive deep into rich insights for new drugs for Pancreatic Cancer Treatment, Visit @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Pancreatic Cancer Market Drivers and Barriers, and Future Perspective<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Pancreatic Cancer: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Pancreatic Cancer &ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Pamrevlumab: FibroGen<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Niraparib: Innovent Biologics<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I\/II)<\/li>\n<li>CT041: CARsgen Therapeutics<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>ONC 212: Oncoceutics<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>Pancreatic Cancer Key Companies<\/li>\n<li>Pancreatic Cancer Key Products<\/li>\n<li>Pancreatic Cancer- Unmet Needs<\/li>\n<li>Pancreatic Cancer- Market Drivers and Barriers<\/li>\n<li>Pancreatic Cancer- Future Perspectives and Conclusion<\/li>\n<li>Pancreatic Cancer Analyst Views<\/li>\n<li>Pancreatic Cancer Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>For further information on the Pancreatic Cancer Pipeline therapeutics, reach out to&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Pancreatic Cancer Unmet Needs and Analyst Views<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=pancreatic-cancer-pipeline-insights-report-2023-updated-erytech-pharma-jiangsu-hengrui-medicine-co-ltd-fibrogen-novartis-ag-ab-science-eleison-pharmaceuticals-cornerstone-pharmaceuticals\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/allergic-asthma-due-to-dermatophagoides-farinae-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/allergic-asthma-due-to-dermatophagoides-farinae-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/allergic-asthma-due-to-dermatophagoides-farinae-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=pancreatic-cancer-pipeline-insights-report-2023-updated-erytech-pharma-jiangsu-hengrui-medicine-co-ltd-fibrogen-novartis-ag-ab-science-eleison-pharmaceuticals-cornerstone-pharmaceuticals\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s, &ldquo;Pancreatic Cancer Pipeline Insight 2023&rdquo; report provides comprehensive insights about 290+ companies and 300+ pipeline drugs in the Pancreatic Cancer pipeline landscape. It covers the Pancreatic Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/pancreatic-cancer-pipeline-insights-report-2023-updated-erytech-pharma-jiangsu-hengrui-medicine-co-ltd-fibrogen-novartis-ag-ab-science-eleison-pharmaceuticals-cornerstone-pharmaceuticals_678969.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-678969","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/678969","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=678969"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/678969\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=678969"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=678969"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=678969"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}